Received Jun 17, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
developed a rash on his arms, slightly on his thighs and on his lower back/that is also itchy; This non-serious case was reported by a consumer via call center representative and described the occurrence of itchy rash in a 85-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection for prophylaxis. On 03-JUN-2026, the patient received Arexvy. In JUN-2026, 2 days after receiving Arexvy, the patient experienced itchy rash (Verbatim: developed a rash on his arms, slightly on his thighs and on his lower back/that is also itchy).The outcome of the itchy rash was not resolved. It was unknown if the reporter considered the itchy rash to be related to Arexvy. Additional Information: GSK Receipt Date:09-JUN-2026 The batch number was not provided and request for the information had been made.